216 related articles for article (PubMed ID: 15979031)
1. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry.
Kitagawa T; Ishige N; Suzuki K; Owada M; Ohashi T; Kobayashi M; Eto Y; Tanaka A; Mills K; Winchester B; Keutzer J
Mol Genet Metab; 2005 Jul; 85(3):196-202. PubMed ID: 15979031
[TBL] [Abstract][Full Text] [Related]
2. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
[TBL] [Abstract][Full Text] [Related]
3. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease.
Mills K; Morris P; Lee P; Vellodi A; Waldek S; Young E; Winchester B
J Inherit Metab Dis; 2005; 28(1):35-48. PubMed ID: 15702404
[TBL] [Abstract][Full Text] [Related]
4. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes.
Kitagawa T; Suzuki K; Ishige N; Ohashi T; Kobayashi M; Eto Y; Tanaka A; Odaka H; Owada M
Pediatr Nephrol; 2008 Sep; 23(9):1461-71. PubMed ID: 18535844
[TBL] [Abstract][Full Text] [Related]
6. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
7. Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease.
Chien YH; Olivova P; Zhang XK; Chiang SC; Lee NC; Keutzer J; Hwu WL
Mol Genet Metab; 2011 Jan; 102(1):57-60. PubMed ID: 20864368
[TBL] [Abstract][Full Text] [Related]
8. Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease.
Boscaro F; Pieraccini G; la Marca G; Bartolucci G; Luceri C; Luceri F; Moneti G
Rapid Commun Mass Spectrom; 2002; 16(16):1507-14. PubMed ID: 12203240
[TBL] [Abstract][Full Text] [Related]
9. Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard.
Fauler G; Rechberger GN; Devrnja D; Erwa W; Plecko B; Kotanko P; Breunig F; Paschke E
Rapid Commun Mass Spectrom; 2005; 19(11):1499-506. PubMed ID: 15880667
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months.
Barr C; Clarke JT; Ntwari A; Drouin R; Auray-Blais C
Mol Genet Metab; 2009 Aug; 97(4):278-83. PubMed ID: 19464216
[TBL] [Abstract][Full Text] [Related]
11. Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit.
Zeidner KM; Desnick RJ; Ioannou YA
Anal Biochem; 1999 Feb; 267(1):104-13. PubMed ID: 9918661
[TBL] [Abstract][Full Text] [Related]
12. [Contribution of the measurement of globotriaosylceramide in urine to the diagnosis and follow-up of Fabry disease].
Piraud M; Maire I; Froissart R
Rev Med Interne; 2010 Dec; 31 Suppl 2():S270-4. PubMed ID: 21211678
[TBL] [Abstract][Full Text] [Related]
13. Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study.
Paschke E; Fauler G; Winkler H; Schlagenhauf A; Plecko B; Erwa W; Breunig F; Urban W; Vujkovac B; Sunder-Plassmann G; Kotanko P
Am J Kidney Dis; 2011 May; 57(5):673-81. PubMed ID: 21186071
[TBL] [Abstract][Full Text] [Related]
14. Is globotriaosylceramide a useful biomarker in Fabry disease?
Young E; Mills K; Morris P; Vellodi A; Lee P; Waldek S; Winchester B
Acta Paediatr Suppl; 2005 Mar; 94(447):51-4; discussion 37-8. PubMed ID: 15895713
[TBL] [Abstract][Full Text] [Related]
15. Immunoelectron-microscopic detection of globotriaosylceramide accumulated in the skin of patients with Fabry disease.
Kanekura T; Fukushige T; Kanda A; Tsuyama S; Murata F; Sakuraba H; Kanzaki T
Br J Dermatol; 2005 Sep; 153(3):544-8. PubMed ID: 16120140
[TBL] [Abstract][Full Text] [Related]
16. Optimisation of the separation of four major neutral glycosphingolipids: application to a rapid and simple detection of urinary globotriaosylceramide in Fabry disease.
Roy S; Gaudin K; Germain DP; Baillet A; Prognon P; Chaminade P
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 805(2):331-7. PubMed ID: 15135109
[TBL] [Abstract][Full Text] [Related]
17. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.
Auray-Blais C; Cyr D; Ntwari A; West ML; Cox-Brinkman J; Bichet DG; Germain DP; Laframboise R; Melançon SB; Stockley T; Clarke JT; Drouin R
Mol Genet Metab; 2008 Mar; 93(3):331-40. PubMed ID: 18023222
[TBL] [Abstract][Full Text] [Related]
18. Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.
Whitfield PD; Calvin J; Hogg S; O'Driscoll E; Halsall D; Burling K; Maguire G; Wright N; Cox TM; Meikle PJ; Deegan PB
J Inherit Metab Dis; 2005; 28(1):21-33. PubMed ID: 15702403
[TBL] [Abstract][Full Text] [Related]
19. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
20. Targeted urine microscopy in Anderson-Fabry disease: a cheap, sensitive and specific diagnostic technique.
Selvarajah M; Nicholls K; Hewitson TD; Becker GJ
Nephrol Dial Transplant; 2011 Oct; 26(10):3195-202. PubMed ID: 21382994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
